FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Longevity Base

Longevityadvanced
15
Share
펩타이드

2

일 평균 mcg

0

수준

advanced

추가됨

May 7, 2026

개요

The Longevity Base is an advanced peptide protocol targeting two fundamental pillars of biological aging: telomere maintenance and systemic tissue repair. By pairing Epithalon, a synthetic tetrapeptide that activates telomerase, with BPC-157, a gastric pentadecapeptide with extraordinary regenerative properties, this stack addresses aging at both the chromosomal and cellular-functional levels. Epithalon at 10mg administered subcutaneously daily for a 10-day cycle directly stimulates telomerase production in somatic cells. Telomerase is the enzyme responsible for maintaining telomere length, the protective caps on chromosomes that shorten with each cell division and serve as a primary biological clock of aging. Research by Professor Vladimir Khavinson, who pioneered Epithalon development, demonstrated measurable telomere elongation, improved neuroendocrine function, and extended lifespan in animal models. The 10-day intensive protocol followed by extended rest periods (typically 4-6 months between cycles) mirrors the pulsatile approach used in clinical research settings. BPC-157 at 250mcg daily provides continuous systemic repair signaling throughout and beyond the Epithalon cycle. This peptide upregulates growth factor expression (VEGF, EGF, and others), promotes angiogenesis, accelerates wound healing, protects and heals gut lining, and demonstrates neuroprotective properties. Its role in this stack is to maintain tissue integrity and repair capacity while Epithalon works at the deeper chromosomal level. Administer Epithalon subcutaneously in the morning during the 10-day intensive phase. BPC-157 can be taken at any consistent time daily and is continued beyond the Epithalon cycle as a maintenance peptide. This stack is designed for advanced users with established health optimization practices who are focused on long-term biological age reduction. It is particularly suited for those over 40 seeking to slow or partially reverse cellular aging markers. The combination is supported by decades of Russian gerontological research on Epithalon and a growing body of literature on BPC-157 systemic repair mechanisms. Users should monitor biomarkers including telomere length testing, inflammatory markers, and hormonal panels to track progress across cycles.

용량 프로토콜

Epithalon

daily for 10 days· subcutaneous

Epithalon에 대한 자세한 내용 →

10mg

1회 용량당

BPC-157

Every day· subcutaneous

BPC-157에 대한 자세한 내용 →

250mcg

1회 용량당

목표 및 증거

증거 등급:community

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.